Mark R. Wieland

24 papers receiving 1.0k citations

Hit Papers

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg...20142026201820222014100200300400

Peers

Mark R. Wieland
Comparison fields: 5 of 66
  • Ophthalmology 972
  • Radiology, Nuclear Medicine and Imaging 770
  • Molecular Biology 155
  • Public Health, Environmental and Occupational Health 76
  • Endocrinology 61
Replace Eric K. Chin with:
Eric K. Chin United States
Sergio E. Hernández-Da Mota Mexico
Göktuğ Demirci Türkiye
Daniel F. Kiernan United States
Jans Fromow-Guerra Mexico
A. Bron France
Reetika Sharma India
Joanna Wasielica‐Poslednik Germany
R C Tripathi United States
Mark R. Wieland relative to Eric K. Chin United States Eric K. Chin's profile →
Citations per field
00.5×2.8×
Eric K. Chin · 1×
Citations per year

Countries citing papers authored by Mark R. Wieland

Since Specialization
Citations

This map shows the geographic impact of Mark R. Wieland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Wieland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Wieland more than expected).

Fields of papers citing papers by Mark R. Wieland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Wieland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Wieland. The network helps show where Mark R. Wieland may publish in the future.

Co-authorship network of co-authors of Mark R. Wieland

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Wieland. A scholar is included among the top collaborators of Mark R. Wieland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Wieland. Mark R. Wieland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 33
2 12
3 9
4 10
5 10
6
Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-Exudative AMD Trial (PREVENT): A prospective controlled clinical trial
2
7 179
8 3
9 24
10 22
11 49
12 5
13 21
14
Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degenerationbreakdown →
486
15 12
16 2
17 1
18 21
19 41
20 3

About Mark R. Wieland

Mark R. Wieland is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Medicine, having authored 24 papers that have together received 1.1k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (16 papers), Retinal and Optic Conditions (9 papers) and Retinal Imaging and Analysis (8 papers). The work is most often cited by research in Ophthalmology (972 citations), Radiology, Nuclear Medicine and Imaging (770 citations) and Endocrinology (61 citations). Mark R. Wieland has collaborated with scholars based in United States, Austria and Switzerland. Frequent co-authors include Brandon Busbee, Allen C. Ho, Phillip Lai, Roman G. Rubio, Carl D. Regillo, Zhengrong Li, Rahul N. Khurana, Lawrence J. Singerman, Andreas Weichselberger and Pravin U. Dugel. Their work appears in journals such as Ophthalmology, American Journal of Ophthalmology and Investigative Ophthalmology & Visual Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026